Postdoctoral Fellow - ALS Drug Screening and Development
April 27, 2018
Full Time - Experienced
Academic / Research
BrainXell has an opening for a post-doctoral fellow in an industry setting immediately. The two-year project is a continuation of our finished SBIR phase I grant (https://www.sbir.gov/sbirsearch/detail/1198159). It is fully funded and provides a fantastic opportunity for a scientist interested in early-stage CNS drug development to lead a project from the earliest stages into animal testing. BrainXell has discovered a compound with a novel activity for the treatment of ALS. Working with a medicinal chemistry consultant and CRO, the scientist will develop a structure-activity relationship around a hit compound and then move into lead optimization. In addition, he or she will conduct follow-on high-throughput screening campaigns with collaborators at the NIH to detect more activity compounds. The individual will design and perform the in vitro efficacy, toxicity, and stability testing to support this work. If suitable compounds are discovered, they will be evaluated in vivo for desired pharmacokinetic properties, blood-brain barrier penetration, and in situ efficacy. This scientist will be intimately involved in all aspects of the project and gain a solid understand of preclinical CNS drug development, with help of other team members. The requirements include a PhD in the biomedical sciences, competency in mammalian cell culture and assay development, and a background in either neuroscience or pharmacology. The applicant must be authorized to be employed by a for-profit entity. Salary will be commensurate with experience; BrainXell offers full health and dental benefits.
BrainXell is a small startup company located in Madison WI (https://news.wisc.edu/brain-cells-by-the-billions-uw-spinoff-sells-neural-cells-to-drug-researchers/). It provides iPSC/ESC-derived human neurons to the pharmaceutical industry and other research organizations for drug discovery and toxicity studies. We are also adapting our cell production technologies to a cGMP environment with ability to efficiently produce large numbers of high-purity neural cells for cell therapy. We have recently moved into a larger space in the beautiful Research Park.
Internal Number: 012
BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells for as well as provide services to pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXell’s goal is to make our brain healthy and well.